OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Society for Immunotherapy of Cancer (SITC) consensus definitions for immune checkpoint inhibitor-associated immune-related adverse events (irAEs) terminology
Jarushka Naidoo, Catherine J. Murphy, Michael B. Atkins, et al.
Journal for ImmunoTherapy of Cancer (2023) Vol. 11, Iss. 3, pp. e006398-e006398
Open Access | Times Cited: 67
Jarushka Naidoo, Catherine J. Murphy, Michael B. Atkins, et al.
Journal for ImmunoTherapy of Cancer (2023) Vol. 11, Iss. 3, pp. e006398-e006398
Open Access | Times Cited: 67
Showing 1-25 of 67 citing articles:
Clinical and translational attributes of immune-related adverse events
Karijn P.M. Suijkerbuijk, Mick J M van Eijs, Femke van Wijk, et al.
Nature Cancer (2024) Vol. 5, Iss. 4, pp. 557-571
Closed Access | Times Cited: 29
Karijn P.M. Suijkerbuijk, Mick J M van Eijs, Femke van Wijk, et al.
Nature Cancer (2024) Vol. 5, Iss. 4, pp. 557-571
Closed Access | Times Cited: 29
Case report: Multi-organ injuries induced by tislelizumab
Man Yuan, Ning Han, Shu Li, et al.
Frontiers in Immunology (2025) Vol. 16
Open Access | Times Cited: 1
Man Yuan, Ning Han, Shu Li, et al.
Frontiers in Immunology (2025) Vol. 16
Open Access | Times Cited: 1
Chronic immune-related adverse events in patients with cancer receiving immune checkpoint inhibitors: a systematic review
Carly C. Barron, Isabella Stefanova, Yevin Cha, et al.
Journal for ImmunoTherapy of Cancer (2023) Vol. 11, Iss. 8, pp. e006500-e006500
Open Access | Times Cited: 33
Carly C. Barron, Isabella Stefanova, Yevin Cha, et al.
Journal for ImmunoTherapy of Cancer (2023) Vol. 11, Iss. 8, pp. e006500-e006500
Open Access | Times Cited: 33
Treatment-related adverse events, including fatal toxicities, in patients with solid tumours receiving neoadjuvant and adjuvant immune checkpoint blockade: a systematic review and meta-analysis of randomised controlled trials
Yu Fujiwara, Nobuyuki Horita, Elio Adib, et al.
The Lancet Oncology (2023) Vol. 25, Iss. 1, pp. 62-75
Closed Access | Times Cited: 27
Yu Fujiwara, Nobuyuki Horita, Elio Adib, et al.
The Lancet Oncology (2023) Vol. 25, Iss. 1, pp. 62-75
Closed Access | Times Cited: 27
Corticosteroid-resistant immune-related adverse events: a systematic review
Eveline Daetwyler, Till Wallrabenstein, David König, et al.
Journal for ImmunoTherapy of Cancer (2024) Vol. 12, Iss. 1, pp. e007409-e007409
Open Access | Times Cited: 10
Eveline Daetwyler, Till Wallrabenstein, David König, et al.
Journal for ImmunoTherapy of Cancer (2024) Vol. 12, Iss. 1, pp. e007409-e007409
Open Access | Times Cited: 10
First-line Systemic Therapy Following Adjuvant Immunotherapy in Renal Cell Carcinoma: An International Multicenter Study
Talal El Zarif, Karl Semaan, Wanling Xie, et al.
European Urology (2024) Vol. 86, Iss. 6, pp. 503-512
Closed Access | Times Cited: 7
Talal El Zarif, Karl Semaan, Wanling Xie, et al.
European Urology (2024) Vol. 86, Iss. 6, pp. 503-512
Closed Access | Times Cited: 7
Unraveling the complex interplay between anti-tumor immune response and autoimmunity mediated by B cells and autoantibodies in the era of anti-checkpoint monoclonal antibody therapies
Sarah Soussan, Guilhem Pupier, Isabelle Cremer, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 6
Sarah Soussan, Guilhem Pupier, Isabelle Cremer, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 6
A scoping review of vasculitis as an immune-related adverse event from checkpoint inhibitor therapy of cancer: Unraveling the complexities at the intersection of immunology and vascular pathology
Chanmi Lee, Margaret Wang, Aarthi Rajkumar, et al.
Seminars in Arthritis and Rheumatism (2024) Vol. 66, pp. 152440-152440
Open Access | Times Cited: 6
Chanmi Lee, Margaret Wang, Aarthi Rajkumar, et al.
Seminars in Arthritis and Rheumatism (2024) Vol. 66, pp. 152440-152440
Open Access | Times Cited: 6
Cancer and treatment specific incidence rates of immune-related adverse events induced by immune checkpoint inhibitors: a systematic review
Bishma Jayathilaka, Firoz Mian, Fanny Franchini, et al.
British Journal of Cancer (2024)
Open Access | Times Cited: 6
Bishma Jayathilaka, Firoz Mian, Fanny Franchini, et al.
British Journal of Cancer (2024)
Open Access | Times Cited: 6
Circulating biomarkers in the diagnosis and prognosis of immune checkpoint inhibitor-related myocarditis: time for a risk-based approach
Gillian Murtagh, Christopher R. deFilippi, Qiong Zhao, et al.
Frontiers in Cardiovascular Medicine (2024) Vol. 11
Open Access | Times Cited: 5
Gillian Murtagh, Christopher R. deFilippi, Qiong Zhao, et al.
Frontiers in Cardiovascular Medicine (2024) Vol. 11
Open Access | Times Cited: 5
Letter: Optimising Prevention of Adverse Events and Antiviral Prophylaxis for HBV ‐Infected HCC Patients Undergoing Immunotherapy
Jialing Wang, Wenjun Meng
Alimentary Pharmacology & Therapeutics (2025)
Open Access
Jialing Wang, Wenjun Meng
Alimentary Pharmacology & Therapeutics (2025)
Open Access
Efficacy of high-dose steroids versus low-dose steroids in the treatment of immune checkpoint inhibitor-associated myocarditis: a case series and systematic review
Xiuyue Man, Hong Wang, Chen Chen, et al.
Frontiers in Immunology (2025) Vol. 16
Open Access
Xiuyue Man, Hong Wang, Chen Chen, et al.
Frontiers in Immunology (2025) Vol. 16
Open Access
Chronicity of Immune Checkpoint Inhibitor–Associated Inflammatory Arthritis After Immunotherapy Discontinuation: Results From the Canadian Research Group of Rheumatology in Immuno‐Oncology Database
Alexandra Ladouceur, Shahin Jamal, Alexandra Saltman, et al.
ACR Open Rheumatology (2025) Vol. 7, Iss. 2
Open Access
Alexandra Ladouceur, Shahin Jamal, Alexandra Saltman, et al.
ACR Open Rheumatology (2025) Vol. 7, Iss. 2
Open Access
What Is the Impact of Novel Systemic Anticancer Therapy on Acute Oncology Education and Service Delivery?
Gina Madera, Ali Hodge, Lara Roskelly, et al.
Seminars in Oncology Nursing (2025), pp. 151842-151842
Closed Access
Gina Madera, Ali Hodge, Lara Roskelly, et al.
Seminars in Oncology Nursing (2025), pp. 151842-151842
Closed Access
Long-Term Toxicity of Immune Checkpoint Inhibitors—Time to Widen the Lens
Christopher Cronin, Aoife O'Sullivan, Jarushka Naidoo
JAMA Oncology (2025)
Closed Access
Christopher Cronin, Aoife O'Sullivan, Jarushka Naidoo
JAMA Oncology (2025)
Closed Access
Immune checkpoint inhibitor-associated myocarditis: a review of current state of knowledge
Keila C. Ostos-Mendoza, Valeria Saraiba-Rabanales, Paola Gutierrez-Gallegos, et al.
The Journal of Cardiovascular Aging (2025) Vol. 5, Iss. 1
Open Access
Keila C. Ostos-Mendoza, Valeria Saraiba-Rabanales, Paola Gutierrez-Gallegos, et al.
The Journal of Cardiovascular Aging (2025) Vol. 5, Iss. 1
Open Access
Hepatoblastoma: From Molecular Mechanisms to Therapeutic Strategies
Fan Ling, Jintong Na, Tieliu Shi, et al.
Current Oncology (2025) Vol. 32, Iss. 3, pp. 149-149
Open Access
Fan Ling, Jintong Na, Tieliu Shi, et al.
Current Oncology (2025) Vol. 32, Iss. 3, pp. 149-149
Open Access
Clinical management of checkpoint inhibitor pneumonitis: Focus, challenges, and future directions
Yan Xu, Ruxuan Chen, Ruili Pan, et al.
Chinese Medical Journal - Pulmonary and Critical Care Medicine (2025)
Open Access
Yan Xu, Ruxuan Chen, Ruili Pan, et al.
Chinese Medical Journal - Pulmonary and Critical Care Medicine (2025)
Open Access
Dual mRNA nanoparticles strategy for enhanced pancreatic cancer treatment and β-elemene combination therapy
Qianru Zhu, Changyuan Yu, Yiquan Chen, et al.
Proceedings of the National Academy of Sciences (2025) Vol. 122, Iss. 11
Open Access
Qianru Zhu, Changyuan Yu, Yiquan Chen, et al.
Proceedings of the National Academy of Sciences (2025) Vol. 122, Iss. 11
Open Access
Toxicity-specific peripheral blood T and B cell dynamics in anti-PD-1 and combined immune checkpoint inhibition
Mick J M van Eijs, Rik J. Verheijden, Stefanie A. van der Wees, et al.
Cancer Immunology Immunotherapy (2023) Vol. 72, Iss. 12, pp. 4049-4064
Open Access | Times Cited: 14
Mick J M van Eijs, Rik J. Verheijden, Stefanie A. van der Wees, et al.
Cancer Immunology Immunotherapy (2023) Vol. 72, Iss. 12, pp. 4049-4064
Open Access | Times Cited: 14
Immunosuppressant mycophenolate mofetil for patients with steroid-refractory immune-related hepatitis induced by checkpoint inhibitors in oncology
Emily Alouani, Ariane Laparra, Audrey Perret, et al.
European Journal of Cancer (2023) Vol. 193, pp. 113313-113313
Closed Access | Times Cited: 12
Emily Alouani, Ariane Laparra, Audrey Perret, et al.
European Journal of Cancer (2023) Vol. 193, pp. 113313-113313
Closed Access | Times Cited: 12
Immunotherapy for early-stage non-small cell lung cancer: A system review
Jingyi Gao, Chao Zhang, Zhigang Wei, et al.
Journal of Cancer Research and Therapeutics (2023) Vol. 19, Iss. 4, pp. 849-865
Open Access | Times Cited: 12
Jingyi Gao, Chao Zhang, Zhigang Wei, et al.
Journal of Cancer Research and Therapeutics (2023) Vol. 19, Iss. 4, pp. 849-865
Open Access | Times Cited: 12
Survivorship outcomes in patients treated with immune checkpoint inhibitors: a scoping review
Deniz Can Güven, Melissa S. Y. Thong, Volker Arndt
Journal of Cancer Survivorship (2024)
Open Access | Times Cited: 4
Deniz Can Güven, Melissa S. Y. Thong, Volker Arndt
Journal of Cancer Survivorship (2024)
Open Access | Times Cited: 4
Rheumatic adverse events of immune checkpoint inhibitors in cancer immunotherapy
Noha Abdel‐Wahab, María E. Suärez-Almazor
Expert Review of Clinical Immunology (2024) Vol. 20, Iss. 8, pp. 873-893
Closed Access | Times Cited: 4
Noha Abdel‐Wahab, María E. Suärez-Almazor
Expert Review of Clinical Immunology (2024) Vol. 20, Iss. 8, pp. 873-893
Closed Access | Times Cited: 4
Dabrafenib plus trametinib versus anti-PD-1 monotherapy as adjuvant therapy in BRAF V600-mutant stage III melanoma after definitive surgery: a multicenter, retrospective cohort study
Xue Bai, Shaheen Ahmed, Charlotte Grieco, et al.
EClinicalMedicine (2023) Vol. 65, pp. 102290-102290
Open Access | Times Cited: 11
Xue Bai, Shaheen Ahmed, Charlotte Grieco, et al.
EClinicalMedicine (2023) Vol. 65, pp. 102290-102290
Open Access | Times Cited: 11
